Loading
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
  • Log In
    • Register
Contacts us @ MediPr.org
Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong Kong
  • MDnews
  • About [‘mediPr]
  • Search
  • Menu Menu
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share by Mail

Non-Sponsored Content


TARGETED THERAPY

CRIZOTINIB BENEFICIAL IN EAST-ASIAN NSCLC-PATIENTS HARBOURING ROS1 ALTERATIONS

Medical writer: Stijn van den Borne, MSc | Last updated: 4th April 2018 | In: China, Lung Cancer, Oncology, Targeted Therapies

Article Keywords

Asian, China, cMET, crizotinib, ELM4-ALK, NSCLC, Oncology News, ROS1, Xalkori

Crizotinib offered a 71.7% objective response rate (ORR) and a median duration of response (DOR) of 19.7 months in East-Asian non-small cell lung cancer (NSCLC) patients harbouring c-ros oncogene 1 (ROS1) rearrangements. This was concluded by investigators from China, Japan, South-Korea, and Taiwan who published the results of the trial in the Journal of Clinical Oncology (JCO) on March 29, 2018.

“Approximately 1% to 2% of NSCLCs harbour a ROS1 rearrangement”, first author Prof. Wu Yi-Long, Guangdong General Hospital and Guangdong Academy of Medical Sciences in Guangzhou, People’s Republic of China, and colleagues wrote in JCO.

The Phase II open-label study enrolled 127 East-Asian patients with confirmed ROS1-positive NSCLC who had received up to three prior lines of systemic therapy. Participants received two oral doses of 250 mg crizotinib daily until progression disease (RECIST 1.1) as confirmed by an independent radiological review (IRR). The primary efficacy endpoint was ORR by IRR.

Crizotinib (XalkoriⓇ, Pfizer Inc.) is an inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and the hepatocyte growth factor receptor (MET).

    Figure 1. Responses observed with crizotinib in East-Asian patients with ROS1-rearranged NSCLC.

    At the time of the data cut-off, 49.6% of patients were still receiving crizotinib-treatment. Seventeen complete responses and 74 partial responses (Figure 1) were observed, translating into an ORR of 71.7% (95% CI, 63.0% – 79.3%) by IRR. Responses were lasting, the median DOR was 19.7 months (95% CI, 14.1 months – not reached), and irrespective of the number of prior lines of therapy The median progression-free survival (PFS) by IRR was 15.9 months (95% CI, 12.9 – 24.0).

    The authors reported no new toxicities. The most common adverse reactions which occur in ≥25% of patients treated with crizotinib are vision disorders, nausea, diarrhoea, vomiting, oedema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory tract infection, dizziness, and neuropathy.

    References

    1. Wu YL et al. J Clin Oncol 2018;JCO2017755587 DOI: 10.1200/JCO.2017.75.5587
    2. Pfizer Inc. XalkoriⓇ (crizotinib) USPI, revised 2/2018


    Newsletter Sign-Up

    Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

    Newsletter

    YOU MAY ALSO LIKE

    U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

    US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

    https://medi-paper.com/wp-content/uploads/2017/08/U.S.-FDA-approved-immunecheckpoint-inhibitors--e1528903094981.jpg 1194 1254 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2020-12-08 18:00:012020-12-10 20:19:55US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020
    detecting metastases with psma pet in prostate cancer

    Detecting metastases with PSMA-PET in prostate cancer

    https://medi-paper.com/wp-content/uploads/2020/12/detecting-metastases-with-psma-pet-in-prostate-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-08 10:03:172020-12-11 15:12:41Detecting metastases with PSMA-PET in prostate cancer
    asco guidelines for the use of systemic therapies in advanced hepatocellular cancer

    ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer

    https://medi-paper.com/wp-content/uploads/2020/12/asco-guidelines-for-the-use-of-systemic-therapies-in-advanced-hepatocellular-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-07 17:20:022020-12-11 14:24:21ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer
    Sotorasib for the treatment of KRASG12C-mutated lung cancer

    Sotorasib for the treatment of KRASG12C mutated lung cancer

    https://medi-paper.com/wp-content/uploads/2020/10/Sotorasib-for-the-treatment-of-KRASG12C-mutated-lung-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-15 10:16:382020-10-15 11:45:13Sotorasib for the treatment of KRASG12C mutated lung cancer
    PreviousNext
    U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer
    8th December 2020

    US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

    detecting metastases with psma pet in prostate cancer
    8th December 2020

    Detecting metastases with PSMA-PET in prostate cancer

    Disclaimer

    This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

    © Copyright 2018 MediPaper Medical Communications Ltd. – Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations – XalkoriⓇ/crizotinib in Asian non-small cell lung cancer patients with ROS-1 alterations

    Share this entry
    • Share on Facebook
    • Share on Twitter
    • Share on WhatsApp
    • Share on Pinterest
    • Share on LinkedIn
    • Share on Tumblr
    • Share by Mail

    YOU MAY ALSO LIKE

    U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

    US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

    https://medi-paper.com/wp-content/uploads/2017/08/U.S.-FDA-approved-immunecheckpoint-inhibitors--e1528903094981.jpg 1194 1254 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2020-12-08 18:00:012020-12-10 20:19:55US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020
    detecting metastases with psma pet in prostate cancer

    Detecting metastases with PSMA-PET in prostate cancer

    https://medi-paper.com/wp-content/uploads/2020/12/detecting-metastases-with-psma-pet-in-prostate-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-08 10:03:172020-12-11 15:12:41Detecting metastases with PSMA-PET in prostate cancer
    asco guidelines for the use of systemic therapies in advanced hepatocellular cancer

    ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer

    https://medi-paper.com/wp-content/uploads/2020/12/asco-guidelines-for-the-use-of-systemic-therapies-in-advanced-hepatocellular-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-07 17:20:022020-12-11 14:24:21ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer
    Sotorasib for the treatment of KRASG12C-mutated lung cancer

    Sotorasib for the treatment of KRASG12C mutated lung cancer

    https://medi-paper.com/wp-content/uploads/2020/10/Sotorasib-for-the-treatment-of-KRASG12C-mutated-lung-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-15 10:16:382020-10-15 11:45:13Sotorasib for the treatment of KRASG12C mutated lung cancer
    Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer

    Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer

    https://medi-paper.com/wp-content/uploads/2020/10/Capmatinib-therapy-for-the-treatment-of-MET-positive-non-small-cell-lung-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-15 09:46:042020-10-15 11:41:25Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer
    Selpercatinib-displays-efficacy-in-RET -fusion-positive-non-small-cell-lung-cancer

    Selpercatinib displays efficacy in RET fusion-positive non-small cell lung cancer

    https://medi-paper.com/wp-content/uploads/2020/09/Selpercatinib-displays-efficacy-in-RET-fusion-positive-non-small-cell-lung-cancer-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-07 21:04:252020-09-07 23:03:18Selpercatinib displays efficacy in RET fusion-positive non-small cell lung cancer

    First liquid biopsy for NSCLC to receive FDA approval

    https://medi-paper.com/wp-content/uploads/2020/09/First-liquid-biopsy-for-NSCLC-to-receive-FDA-approval-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-07 10:09:062020-09-08 09:56:03First liquid biopsy for NSCLC to receive FDA approval
    ESMO-releases-the-first-guideline-on-NGS-testing- in-cancers

    ESMO releases the first guideline on NGS testing in cancers

    https://medi-paper.com/wp-content/uploads/2020/09/ESMO-releases-the-first-guideline-on-NGS-testing-in-cancers-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-07 09:36:352020-09-08 08:52:38ESMO releases the first guideline on NGS testing in cancers
    residual-risk-of-hepatocellular-carcinoma-in-older-hepatitis-c-patients-even-after-viral-clearance

    Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance

    https://medi-paper.com/wp-content/uploads/2020/08/residual-risk-of-hepatocellular-carcinoma-in-older-hepatitis-c-patients-even-after-viral-clearance-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-13 16:18:002020-08-17 16:56:12Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance
    updated-human-papillomavirus-vaccination-and-testing-recommendations-from-the-american-cancer-society

    Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society

    https://medi-paper.com/wp-content/uploads/2020/08/updated-human-papillomavirus-vaccination-and-testing-recommendations-from-the-american-cancer-society-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-13 14:41:322020-08-25 14:37:07Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society
    Lower-risk-MDS-patients-benefit-from-novel-drug-imetelstat

    Lower-risk MDS patients benefit from novel drug, imetelstat

    https://medi-paper.com/wp-content/uploads/2020/07/Lower-risk-MDS-patients-benefit-from-novel-drug-imetelstat.jpg 844 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-07-10 17:24:512020-08-11 09:56:13Lower-risk MDS patients benefit from novel drug, imetelstat
    Carboplatin plus paclitaxel to be the new standard of care for anal cancer

    Carboplatin plus paclitaxel to be the new standard of care for anal cancer

    https://medi-paper.com/wp-content/uploads/2020/07/Carboplatin-plus-paclitaxel-to-be-the-new-standard-of-care-for-anal-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-07-10 17:24:482020-08-11 09:52:36Carboplatin plus paclitaxel to be the new standard of care for anal cancer
    ASCO 2020 ASCO20 virtual meeting NSCLC SCLC lung cancer breast cancer hepatocellular cancer HCC colorectal cancer CRC

    ASCO 2020 Lung, Breast, and Liver Cancer Update

    https://medi-paper.com/wp-content/uploads/2020/06/ASCO-2020-ASCO20-virtual-meeting-NSCLC-SCLC-lung-cancer-breast-cancer-hepatocellular-cancer-HCC-colorectal-cancer-CRC-e1593749874717.jpg 794 1500 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-06-30 09:37:482020-09-24 12:33:53ASCO 2020 Lung, Breast, and Liver Cancer Update
    Gastric Cancer ramucirumab cyramza pembrolizumab keytruda trastuzumab herceptin dMMR MSI HER2 VEGF VEGFR gastric adenocarcinoma GEJ gastroesophageal junction cancer

    Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong

    https://medi-paper.com/wp-content/uploads/2020/04/gastric-adenocarcinoma-ramucirumab-cyramza-pembrolizumab-nivolumab-trastuzumab-dmmr-msi-her2-vegf-vegfr-gastric-cancer-gej-gastroesophageal-junction-cancer-pd-1-pd-l1-eli-lilly-lilly.png 850 1500 陳穎樂醫生 https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png 陳穎樂醫生2020-04-30 14:03:452020-07-22 16:44:08Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong
    Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

    Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

    https://medi-paper.com/wp-content/uploads/2020/02/Capivasertib-added-to-fulvestrant-improves-progression-free-survival-in-advanced-breast-cancer-patients.jpg 1000 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-02-19 23:37:222020-02-21 10:24:39Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients
    Capivasertib combined with paclitaxel improves survival of metastatic triple-negative breast cancer patients

    Capivasertib plus paclitaxel improves survival of metastatic triple-negative breast cancer patients

    https://medi-paper.com/wp-content/uploads/2019/12/Capivasertib-combined-with-paclitaxel-improves-survival-of-metastatic-triple-negative-breast-cancer-patients-e1582170747234.jpg 1000 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-02-11 17:30:382020-02-11 23:17:00Capivasertib plus paclitaxel improves survival of metastatic triple-negative breast cancer patients
    Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

    Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

    https://medi-paper.com/wp-content/uploads/2019/12/Olaparib-plus-Bevacizumab-as-Maintenance-Therapy-in-Ovarian-Cancer.jpg 844 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-01-24 16:32:552020-01-24 16:40:07Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer
    ADDING RIBOCICLIB TO FULVESTRANT IMPROVES THE SURVIVAL OF ADVANCED BREAST CANCER PATIENTS MONALEESA-3

    Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer

    https://medi-paper.com/wp-content/uploads/2020/01/ADDING-RIBOCICLIB-TO-FULVESTRANT-IMPROVES-THE-SURVIVAL-OF-ADVANCED-BREAST-CANCER-PATIENTS-MONALEESA-3-scaled.jpg 1056 1500 Christy HC CHEUNG, BSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Christy HC CHEUNG, BSc2020-01-12 23:33:152020-01-13 10:41:47Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer
    ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS

    ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

    https://medi-paper.com/wp-content/uploads/2019/06/ASCO-2019-lung-cancer-NSCLC-ASCO19-SCLC-mesothelioma-KEYNOTE-189-KEYNOTE-001-IMpower150-MYSTIC-LCMC3-Lung-MAP-S1400G-S1400I-Flaura-CALGB-30901-DETERRED-COMPASS-.png 1000 750 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-06-12 14:12:322019-06-12 16:51:35ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised
    paclitaxel, cobimetinib, Cotellic, MEK, Exelixis, atezolizumab, Tecentriq, nab-paclitaxel pembrolizumab, Keytruda, Merck, MSD, eribulin mesylate, Halaven, pertuzumab, trastuzumab, Herceptin, Perjeta, docetaxel, Taxotere, Sanofi, trastuzumab-dkst, Ogivri, Mylan, Biocon, margetuximab, MacroGenics, capecitabine, Xeloda, Genentech, gemcitabine, Gemzar, vinolrebine, pyrotinib, Jiangsu HengRui Medicine, neratinib, Nerlynx, Puma, lapatinib, Tykerb, carboplatin, T-DM1, ado-trastuzumab emtansine, Kadcyla doxorubicin, cisplatin, olaparib, Lynparza, cyclophosphamide, epirubicin, Ellence, Pharmorubicin, letrozole, Femara, Novartis, AI, NSAI, capivasertib, capivasertib, AZD5363, AKT, hormonal therapy, endocrine therapy, CDK4/6, RAD001, mTOR, fulvestrant, Faslodex, abemaciclib, Verzenio, Eli Lilly, ribociclib, Kisqali, goserilin, Zoladex, AstraZeneca, everolimus, Afinitor, exemestane, Aromasin, Pfizer, palbociclib, Ibrance, #ASCO2019, AKT1, AZ, BRCA, chemotherapy, CNS metastases, ER-positive, ESR1, GnRH, HER2-negative, HER2-positive, HR-positive, LABC, neoadjuvant, OfS, PARP, PARPi, pCR, PD-L1, postmenopausal, PR-positive, premenopausal, RB1, TAC, taxane, TNBC, trastuzumab, triptorelin

    ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

    https://medi-paper.com/wp-content/uploads/2019/05/ASCO-2019-breast-cancer-TNBC-MBC-ABC-ASCO19-MONALEESA-7-TRINITI-1-FAKTION-TBCRC030-NeoSTOP-ETNA-GeparOLA-KRISTINE-PREDIX-CLEOPATRA-HERITAGE-SOPHIA-NALA-IMpassion-130-Tapur-Colet.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-06-03 16:53:572019-06-04 14:34:55ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

    Venetoclax FDA approved for CLL and SLL

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-15 16:19:292019-05-23 12:36:08Venetoclax FDA approved for CLL and SLL

    FDA approves avelumab plus axitinib for renal cell carcinoma

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-05-14 16:22:572019-05-22 22:49:14FDA approves avelumab plus axitinib for renal cell carcinoma

    Ramucirumab FDA approved for hepatocellular carcinoma

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-10 16:24:042019-05-23 11:58:38Ramucirumab FDA approved for hepatocellular carcinoma

    T-DM1 FDA approved for early breast cancer

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-03 16:24:342019-05-22 22:14:15T-DM1 FDA approved for early breast cancer

    Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-05-02 16:25:032019-05-22 22:14:36Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation
    Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

    Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

    https://medi-paper.com/wp-content/uploads/2019/04/Can-a-novel-temporary-and-fully-resorbable-surgical-implant-improve-the-outcome-of-common-hockey-and-soccer-injuries.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-04-26 20:05:262019-04-26 20:12:32Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

    Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced renal cell carcinoma patients

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-04-26 00:34:542019-04-26 00:38:58Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced renal cell carcinoma patients
    KEYNOTE-158 pembrolizumab in previously treated advanced cervical cancer

    KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

    https://medi-paper.com/wp-content/uploads/2019/04/KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancer.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-04-24 18:22:142019-04-24 18:22:14KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer
    Atezolizumab with or without cobimetinib vs regorafenib for previously treated metastatic colorectal cancer IMblaze370

    Atezolizumab +/- cobimetinib vs regorafenib for previously treated metastatic colorectal cancer (IMblaze370)

    https://medi-paper.com/wp-content/uploads/2019/04/Atezolizumab-with-or-without-cobimetinib-vs-regorafenib-for-previously-treated-metastatic-colorectal-cancer-IMblaze370.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-04-22 21:21:372019-04-22 21:57:04Atezolizumab +/- cobimetinib vs regorafenib for previously treated metastatic colorectal cancer (IMblaze370)

    Palbociclib approved for the treatment of male breast cancer 

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-04-22 16:13:232019-04-22 21:56:34Palbociclib approved for the treatment of male breast cancer 

    Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-04-22 14:35:132019-04-22 21:56:48Erdafitinib FDA approved for the treatment of metastatic urothelial carcinoma

    Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-03-23 09:39:402019-03-23 09:41:21Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)

    Atezolizumab FDA approved for PD-L1 positive unresectable triple-negative breast cancer

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-03-09 23:15:272019-03-09 23:15:27Atezolizumab FDA approved for PD-L1 positive unresectable triple-negative breast cancer
    Immunoncology I-O drugs and immunotherapy for renal cancer RCC

    Combinations: upcoming treatment strategies in metastatic renal cell carcinoma

    https://medi-paper.com/wp-content/uploads/2019/02/Immunoncology-I-O-drugs-and-immunotherapy-for-renal-cancer-RCC-.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-03-05 11:13:432019-03-07 14:27:09Combinations: upcoming treatment strategies in metastatic renal cell carcinoma

    Trifluridine/tipiracil combination FDA approved for metastatic gastric or GEJ adenocarcinoma

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-02-23 15:05:352019-03-08 17:00:25Trifluridine/tipiracil combination FDA approved for metastatic gastric or GEJ adenocarcinoma

    Pembrolizumab FDA approved for adjuvant treatment of melanoma

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-02-16 14:55:172019-03-07 14:56:16Pembrolizumab FDA approved for adjuvant treatment of melanoma

    Trastuzumab-biosimilar Ontruzant® FDA approved in several indications

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-01-21 23:16:452019-04-22 16:24:29Trastuzumab-biosimilar Ontruzant® FDA approved in several indications

    Cabozantinib FDA approved in HCC patients failing sorafenib

    https://medi-paper.com/wp-content/uploads/2018/11/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2019-01-17 10:35:362019-02-18 13:23:29Cabozantinib FDA approved in HCC patients failing sorafenib
    Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

    Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

    https://medi-paper.com/wp-content/uploads/2019/01/Erasmus-University-MC-investigating-a-new-surgical-matrix-to-reduce-post-operative-complications.jpg 900 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-01-16 22:58:582019-01-16 23:09:21Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

    Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-01-14 15:36:172019-01-14 15:43:55Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma

    Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-27 16:16:402018-12-27 16:16:40Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

    Elzonris™ FDA approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN)

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-27 15:51:482018-12-27 15:53:57Elzonris™ FDA approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN)

    Olaparib (Lynparza) FDA approved as maintenance for BRCAm ovarian cancer

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-22 16:54:192018-12-22 16:54:19Olaparib (Lynparza) FDA approved as maintenance for BRCAm ovarian cancer

    Trastuzumab-biosimilar Herzuma® FDA approved in HER2+ breast cancer

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-21 15:19:112018-12-21 15:32:40Trastuzumab-biosimilar Herzuma® FDA approved in HER2+ breast cancer

    Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-11 13:21:272018-12-11 13:22:23Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC
    MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

    MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab

    https://medi-paper.com/wp-content/uploads/2018/12/Depositphotos_159314198_xl-2015.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-05 22:00:342018-12-13 13:22:27MURANO: off-drug progression-free survival after 2 years venetoclax plus 6 cycles Rituximab
    TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

    TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

    https://medi-paper.com/wp-content/uploads/2018/12/TIGR®Matrix-shows-promising-results-when-used-for-incisional-hernia-prevention-in-septic-patients-undergoing-laparoscopy.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-12-04 21:28:362018-12-05 11:50:08TIGR®Matrix shows promising results when used for incisional hernia prevention in septic patients undergoing laparoscopy

    Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-29 15:08:432018-11-29 15:11:38Gilteritinib (Xospata®) FDA approved for relapsed or refractory AML harbouring FLT3 mutations

    TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-28 17:00:152018-11-28 18:03:05TKR inhibitor larotrectinib (Vitrakvi®) FDA approved for cancers with NTRK gene fusion

    FDA Approves Truxima as Biosimilar to Rituxan

    https://medi-paper.com/wp-content/uploads/2018/11/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-11-28 14:34:182019-11-12 15:16:57FDA Approves Truxima as Biosimilar to Rituxan

    Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-23 23:17:102018-11-23 23:24:03Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients

    Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-23 22:43:422018-11-23 22:43:42Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients
    Robert Lewandowski Y90 TARE TheraSphere The Emerging Role of Yttrium90 in Primary and Metastatic Liver Cancer hepatocellular carcinoma hcc

    The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer

    https://medi-paper.com/wp-content/uploads/2018/11/Y90-TARE-TheraSphere-The-Emerging-Role-of-Yttrium-90-in-Primary-and-Metastatic-Liver-Cancer..jpg 844 1500 Adrian YIP https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Adrian YIP2018-11-22 22:48:462018-12-11 10:42:29The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer

    Emapalumab FDA approved in adult and paediatric patients with primary hemophagocytic lymphohistiocytosis

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 23:38:102018-11-21 23:49:14Emapalumab FDA approved in adult and paediatric patients with primary hemophagocytic lymphohistiocytosis

    Brentuximab vedotin (Adcetris®) plus chemotherapy approved for several CD30 expressing lymphomas

    https://medi-paper.com/wp-content/uploads/2018/11/1542721242_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 23:01:122018-11-21 23:05:07Brentuximab vedotin (Adcetris®) plus chemotherapy approved for several CD30 expressing lymphomas
    Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

    Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

    https://medi-paper.com/wp-content/uploads/2018/11/Fully-resorbable-synthetic-matrix-offers-improved-safety-for-breast-cancer-patients-undergoing-immediate-breast-reconstruction.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-21 16:41:202018-12-04 21:34:06Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

    Pembrolizumab FDA approved in hepatocellular carcinoma patients pretreated with sorafenib

    https://medi-paper.com/wp-content/uploads/2018/10/1540992382_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-19 11:11:132018-11-19 13:45:58Pembrolizumab FDA approved in hepatocellular carcinoma patients pretreated with sorafenib

    Lorlatinib FDA approved for metastatic ALK-positive NSCLC

    https://medi-paper.com/wp-content/uploads/2018/10/1540992382_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-06 11:30:052018-11-06 11:32:59Lorlatinib FDA approved for metastatic ALK-positive NSCLC
    ESMO 2018 HCC ESMO18 Liver Cancer ESMO2018 hepatocellular carcinoma hepatobiliary cholangiocarcinoma BTC

    ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

    https://medi-paper.com/wp-content/uploads/2018/10/esmo-2018-hcc-esmo18-liver-cancer-esmo-2018-hepatocellular-carcinoma-hepatobilliary-cholangiocarcinoma-btc-.png 1001 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-11-03 17:30:562018-11-05 12:51:54ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

    Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC

    https://medi-paper.com/wp-content/uploads/2018/10/1540992382_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-11-01 10:49:132018-11-01 10:53:51Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC
    Dr Joanne Chiu HKU management irAE hepatitis manage immune-mediated hepatitis immunotherapy I-O immunooncology immune-induced hepatitis

    Management of Immune-Mediated Hepatitis: a Case Report

    https://medi-paper.com/wp-content/uploads/2018/04/management-irAE-hepatitis-manage-immune-mediated-hepatitis-immunotherapy-I-O-immunooncology-immune-induced-hepatitis--e1542867473384.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-10-31 05:53:132018-11-22 15:01:08Management of Immune-Mediated Hepatitis: a Case Report

    PARPi talazoparib FDA approved for deleterious gBRCAm HER2‑negative breast cancer

    https://medi-paper.com/wp-content/uploads/2018/10/1539706020_FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-18 20:50:302018-10-18 21:12:52PARPi talazoparib FDA approved for deleterious gBRCAm HER2‑negative breast cancer
    innovent biologics anti-pd1 sintilimab plus biosimilar bevacizumab receive ind status by china nmpa

    Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

    https://medi-paper.com/wp-content/uploads/2018/10/innovent-biologics-anti-pd1-sintilimab-plus-biosimilar-bevacizumab-receive-ind-status-by-china-nmpa-e1539612467836.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-15 22:26:302018-10-17 11:29:45Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA
    IMpower133 first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

    IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

    https://medi-paper.com/wp-content/uploads/2018/10/IMpower133-first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung-cancer-e1539272789598.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-11 23:48:162018-10-17 11:29:19IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
    Pembrolizumab plus chemotherapy effective in squamous NSCLC

    Pembrolizumab plus chemotherapy effective in squamous NSCLC

    https://medi-paper.com/wp-content/uploads/2018/10/Pembrolizumab-plus-chemotherapy-effective-in-squamous-NSCLC.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-08 00:43:132018-10-17 11:27:05Pembrolizumab plus chemotherapy effective in squamous NSCLC
    Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

    Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

    https://medi-paper.com/wp-content/uploads/2018/10/Ipilimumab-plus-nivolumab-for-persistent-or-recurrent-ovarian-cancer.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-07 00:13:112018-10-17 11:26:28Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer
    Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

    Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

    https://medi-paper.com/wp-content/uploads/2018/10/Brigatinib-prolongs-PFS-compared-to-crizotinib-in-ALK-Positive-NSCLC.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-05 17:27:422018-10-17 11:25:12Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC
    CAR-T axicabtagene ciloleucel granted Orphan Drug Designation for B-Cell Lymphoma by the Japan MHLW

    CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

    https://medi-paper.com/wp-content/uploads/2018/10/CAR-T-axicabtagene-ciloleucel-granted-Orphan-Drug-Designation-for-B-Cell-Lymphoma-by-the-Japan-MHLW.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-05 15:24:252018-10-17 11:23:17CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

    PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)

    https://medi-paper.com/wp-content/uploads/2018/10/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-03 12:53:562018-10-17 11:20:52PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)
    JAVELIN Lung 200 avelumab vs docetaxel in patients with pretreated advanced non-small cell lung cancer NSCLC

    JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

    https://medi-paper.com/wp-content/uploads/2018/10/JAVELIN-Lung-200-avelumab-vs-docetaxel-in-patients-with-pretreated-advanced-non-small-cell-lung-cancer-NSCLC.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-10-02 01:01:252018-10-17 11:18:32JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

    Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC

    https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-28 23:18:162018-10-17 11:17:46Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC
    MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

    Duvelisib FDA approved for adult patients with R/R CLL or SLL

    https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-25 17:33:572018-09-25 17:46:01Duvelisib FDA approved for adult patients with R/R CLL or SLL
    MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

    Duvelisib FDA approved for adult patients with R/R follicular lymphoma

    https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-25 17:20:472018-09-25 17:36:29Duvelisib FDA approved for adult patients with R/R follicular lymphoma
    Front-line atezolizumab plus chemotherapy improves PFS in NSCLC

    Frontline atezolizumab plus chemotherapy improves PFS in NSCLC

    https://medi-paper.com/wp-content/uploads/2018/09/Front-line-atezolizumab-plus-chemotherapy-improves-PFS-in-NSCLC.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-25 10:01:562018-09-25 10:11:35Frontline atezolizumab plus chemotherapy improves PFS in NSCLC
    First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

    First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

    https://medi-paper.com/wp-content/uploads/2018/09/First-line-osimertinib-vs-EGFR-TKI-in-Asian-patients-with-advanced-NSCLC.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-24 13:24:282018-09-24 15:25:11First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC
    Early breast cancer treatment in China remains conservative

    Early breast cancer treatment in China remains conservative

    https://medi-paper.com/wp-content/uploads/2018/09/Early-breast-cancer-treatment-in-China-remains-conservative.jpg 1000 1510 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-23 23:35:002018-09-23 23:39:31Early breast cancer treatment in China remains conservative
    immuno-oncology I-O treatment for the irAE Rash©MediPaper Medical Communications Ltd

    ImmunoOncology: Dr Oscar Chan on the treatment of irAE rash

    https://medi-paper.com/wp-content/uploads/2018/06/immuno-oncology-I-O-treatment-for-the-irAE-Rash.png 786 752 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-21 01:15:492018-09-21 13:29:44ImmunoOncology: Dr Oscar Chan on the treatment of irAE rash
    Prof Stefan Kasper on I-O in EXTREME-ineligible Head and Neck Cancer I-O in SCCHN with focus on EXTREME-ineligible Patients and the future directions of combination immunotherapy

    Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN

    https://medi-paper.com/wp-content/uploads/2018/02/Prof-Stefan-Kasper-on-I-O-in-EXTREME-ineligible-Head-and-Neck-Cancer-I-O-in-SCCHN-with-focus-on-EXTREME-ineligible-Patients-and-the-future-directions-of-combination-immunotherapy.jpg 924 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-19 12:54:212018-09-21 14:01:09Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN
    Camrelizumab anti-PD-1 with or without Chemotherapy for NPC

    Camrelizumab anti-PD-1 with or without chemotherapy for NPC

    https://medi-paper.com/wp-content/uploads/2018/09/Camrelizumab-anti-PD-1-with-or-without-Chemotherapy-for-NPC-e1537238880148.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-18 09:52:592018-09-18 09:55:32Camrelizumab anti-PD-1 with or without chemotherapy for NPC
    MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

    Moxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia

    https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-14 14:20:432018-09-14 14:20:43Moxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia
    Adrian TSE HKIOC irAE pneumonitis lung immunotherapy-induced pneumonitis I-O Immuno-Oncology cannonball metastases cancer©MediPaper Medical Communications Ltd

    I-O in Special Populations: the Treatment of Immunotherapy-Induced Pneumonitis

    https://medi-paper.com/wp-content/uploads/2017/11/Adrian-TSE-HKIOC-irAE-pneumonitis-lung-immunotherapy-induced-pneumonitis-I-O-Immuno-Oncology-cannonball-metastases-cancer.jpg 838 798 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-09-14 13:13:492018-09-21 13:56:54I-O in Special Populations: the Treatment of Immunotherapy-Induced Pneumonitis
    MediPr medipr.org medi-paper.com MediNews Asia MediNews.asia MediNews.cn MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港©United States Food and Drug Agency US FDA

    Venetoclax FDA label updated to include Minimal Residual Disease negativity data

    https://medi-paper.com/wp-content/uploads/2018/09/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.--e1537925034955.png 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-12 22:26:092018-09-14 14:25:02Venetoclax FDA label updated to include Minimal Residual Disease negativity data
    Quizartinib Receives Orphan Drug Designation for FLT3-Mutated AML in Japan

    Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan

    https://medi-paper.com/wp-content/uploads/2018/09/Quizartinib-Receives-Orphan-Drug-Designation-for-FLT3-Mutated-AML-in-Japan.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-12 22:21:342018-09-12 22:21:34Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan
    Lung Cancer Capmatinib plus gefitinib promising in MET-dysregulated NSCLC MediPaper Medical Communications Medical Writer Hong Kong 醫學寫作 醫學作家香港© Eraxion / 123RF Stock Photo

    Capmatinib plus gefitinib promising in MET-dysregulated NSCLC

    https://medi-paper.com/wp-content/uploads/2018/09/Lung-Cancer-Capmatinib-plus-gefitinib-promising-in-MET-dysregulated-NSCLC-MediPaper-Medical-Communications-Medical-Writer-Hong-Kong-醫學寫作-醫學作家香港.png 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-11 21:33:342018-09-11 21:48:36Capmatinib plus gefitinib promising in MET-dysregulated NSCLC
    CAR-TCR Summit 2018 Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer© Royaltystockphoto / 123RF Stock Photo

    CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

    https://medi-paper.com/wp-content/uploads/2018/09/CAR-TCR-Summit-2018-Preliminary-first-in-human-data-with-CAR-Claudin18.2-T-in-gastric-and-pancreatic-cancer.jpg 1054 1505 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-09 09:38:282018-09-09 09:38:28CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer
    DRIVER connects cancer patients in China and the United States to the best care© Kentoh / 123RF Stock Photo

    DRIVER connects cancer patients in China and the United States to the best care

    https://medi-paper.com/wp-content/uploads/2018/09/DRIVER-connects-cancer-patients-in-China-and-the-United-States-to-the-best-care.jpg 994 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-07 21:45:362018-09-07 21:45:36DRIVER connects cancer patients in China and the United States to the best care
    Blood-based TMB-assay predicts response to atezolizumab in NSCLC patients

    Plasma TMB predicts response to atezolizumab in NSCLC patients

    https://medi-paper.com/wp-content/uploads/2018/08/Blood-based-TMB-assay-predicts-response-to-atezolizumab-in-NSCLC-patients.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-31 07:42:492018-08-31 14:33:03Plasma TMB predicts response to atezolizumab in NSCLC patients
    First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation© luchschen / 123RF Stock Photo

    First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

    https://medi-paper.com/wp-content/uploads/2018/08/First-in-Class-Oncology-Vaccine-BIL06v-Starts-Phase-1-Evaluation.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-22 11:48:172018-08-27 09:35:59First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation
    Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)© FDA

    Pembrolizumab and atezolizumab USPIs updated by FDA

    https://medi-paper.com/wp-content/uploads/2018/08/fda-e1537925353881.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-21 12:10:412018-08-21 13:18:15Pembrolizumab and atezolizumab USPIs updated by FDA
    Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)© FDA

    Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

    https://medi-paper.com/wp-content/uploads/2018/08/fda-e1537925353881.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-21 11:24:202018-08-23 10:48:02Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)
    Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

    Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC

    https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lenvatinib-capsules-Lenvima-Eisai-Inc.-for-1st-line-treatment-of-patients-with-unresectable-hepatocellular-carcinoma-HCC.-More-Information-.-August-16-2018-e1537925351885.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-21 10:34:252018-08-21 11:37:56Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC
    Talazoparib in advanced breast cancer patients with a germline BRCA1:2 mutation

    Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation

    https://medi-paper.com/wp-content/uploads/2018/08/Talazoparib-in-advanced-breast-cancer-patients-with-a-germline-BRCA12-mutation.jpg 687 1030 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-19 01:07:502018-08-21 21:55:19Talazoparib in advanced breast cancer patients with a germline BRCA1/2 mutation
    CheckMate 032 Nivolumab ipilimumab metastatic esophagogastric cancer

    CheckMate 032: Nivolumab +/- ipilimumab for metastatic esophagogastric cancer

    https://medi-paper.com/wp-content/uploads/2018/08/CheckMate-032-Nivolumab-ipilimumab-metastatic-esophagogastric-cancer.jpg 667 1000 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-18 23:22:562018-08-19 01:08:26CheckMate 032: Nivolumab +/- ipilimumab for metastatic esophagogastric cancer
    Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

    Lenvatinib FDA approved for 1st-line treatment of HCC

    https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lenvatinib-capsules-Lenvima-Eisai-Inc.-for-1st-line-treatment-of-patients-with-unresectable-hepatocellular-carcinoma-HCC.-More-Information-.-August-16-2018-e1537925351885.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-18 15:50:342018-08-21 22:35:40Lenvatinib FDA approved for 1st-line treatment of HCC
    Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China©Alex011973 / 123RF Stock Photo

    Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

    https://medi-paper.com/wp-content/uploads/2018/08/Pan-EGFR-TKI-pirotinib-has-commenced-into-Phase-II-clinical-testing-in-China.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-13 23:09:022018-09-07 21:59:21Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China
    FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information.  July 31, 2018.

    FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL

    https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-09 00:58:382018-08-12 12:28:54FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL
    FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information.  July 31, 2018.

    Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients

    https://medi-paper.com/wp-content/uploads/2018/08/FDA-approved-lusutrombopag-Mulpleta-Shionogi-Inc.-for-thrombocytopenia-in-adults-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-medical-or-dental-procedure.-More-Information.-July-31-2018-e1537925382959.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-01 09:21:032018-08-12 16:46:52Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    Iobenguane I-131 FDA approved for rare adrenal neuroendocrine tumours

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-31 15:44:032018-07-31 15:45:41Iobenguane I-131 FDA approved for rare adrenal neuroendocrine tumours
    T790M osimertinib nsclc brain metastasis CNS metastases Osimertinib in patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer and brain metastases AURA3© srr283/123RF

    Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)

    https://medi-paper.com/wp-content/uploads/2018/08/T790M-osimertinib-nsclc-CNS-brain-metastasis-Osimertinib-in-patients-With-T790M-Positive-Advanced-Non-Small-Cell-Lung-Cancer-and-brain-metastases-AURA3.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-30 23:43:262018-08-20 12:36:41Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)
    Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

    Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

    https://medi-paper.com/wp-content/uploads/2018/08/Anti-PD1-with-Cemiplimab-in-Advanced-Cutaneous-Squamous-Cell-Carcinoma.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-26 23:44:412018-08-22 23:58:36Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-23 11:33:402018-07-30 10:43:08Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia
    FDA approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). More Information.  July 13, 2018

    Filgrastim-aafi FDA approved as Filgrastim Biosimilar

    https://medi-paper.com/wp-content/uploads/2018/07/FDA-approved-enzalutamide-XTANDI-Astellas-Pharma-US-Inc.-for-patients-with-castration-resistant-prostate-cancer-CRPC.-More-Information-.-July-13-2018-e1537925607982.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-20 10:58:232018-08-11 23:55:01Filgrastim-aafi FDA approved as Filgrastim Biosimilar
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    Ribociclib FDA label updated to include pre- and perimenopausal women

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-19 01:01:572018-07-30 10:42:22Ribociclib FDA label updated to include pre- and perimenopausal women
    FDA approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). More Information.  July 13, 2018

    Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)

    https://medi-paper.com/wp-content/uploads/2018/07/FDA-approved-enzalutamide-XTANDI-Astellas-Pharma-US-Inc.-for-patients-with-castration-resistant-prostate-cancer-CRPC.-More-Information-.-July-13-2018-e1537925607982.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-17 10:14:112018-07-30 10:42:09Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)
    EBV pembrolizumab gastric cancer - MSI-H pembrolizumab gastric cancer - CPS pembrolizumab gastric cancer - MSI, EBV, CPS predict pembrolizumab outcome in gastric cancer© abhijith3747/123RF

    EBV, MSI, and CPS predict pembrolizumab outcome in gastric cancer

    https://medi-paper.com/wp-content/uploads/2018/08/EBV-pembrolizumab-gastric-cancer-MSI-H-pembrolizumab-gastric-cancer-CPS-pembrolizumab-gastric-cancer-MSI-EBV-CPS-predict-pembrolizumab-outcome-in-gastric-cancer.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-16 14:03:432018-08-31 08:15:52EBV, MSI, and CPS predict pembrolizumab outcome in gastric cancer
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated mCRC

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-11 20:52:132018-07-30 10:41:58Ipilimumab plus nivolumab FDA approved for MSI-H and dMMR pre-treated mCRC
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-02 22:14:052018-07-30 10:41:23Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved
    ASCO 2018 nsclc immunotherapy ASCO18 lung cancer pembrolizumab avelumab nivolumab duravalumab ipilimumab osimertinib dacomitinib lorlatinib crizotinib alectinib keytruda KEYNOTE CheckMate JAVELIN IMpower©eraxion / 123RF Stock Photo

    ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

    https://medi-paper.com/wp-content/uploads/2018/06/ASCO-2018-nsclc-immunotherapy-ASCO18-lung-cancer-pembrolizumab-avelumab-nivolumab-duravalumab-ipilimumab-osimertinib-dacomitinib-lorlatinib-crizotinib-alectinib-keytruda-KEYNOTE-CheckMate-JAVELIN-IMpower.jpg 1000 1500 Anne John Michael https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Anne John Michael2018-06-25 18:22:252018-08-21 11:43:54ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised
    FDA  has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.  More Information.  June 19, 2018

    FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma

    https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-19 14:01:322018-07-30 10:40:51FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma
    ASCO 2018 breast cancer TNBC MBC ABC ASCO18 PHEREXA D-CARE ABCSG-18 ASTRRA TEXT SOFT MONARCH-2 MONALEESA-3 SANDPIPER BOLERO-6 TOPACIO KEYNOTE-162 TONIC TOPACIO GeparNeuvo©eraxion / 123RF Stock Photo

    ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised

    https://medi-paper.com/wp-content/uploads/2018/06/ASCO-2018-breast-cancer-TNBC-MBC-ABC-ASCO18-PHEREXA-D-CARE-ABCSG-18-ASTRRA-TEXT-SOFT-MONARCH-2-MONALEESA-3-SANDPIPER-BOLERO-6-TOPACIO-KEYNOTE-162-TONIC-TOPACIO-GeparNeuvo.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-06-19 09:02:512018-06-19 23:57:08ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-14 22:56:042018-07-30 10:40:22Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-14 22:42:142018-07-30 10:40:10FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-13 21:59:012018-07-30 10:39:54FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 
    ASCO18 ASCO 2018 HCC hepatocellular carcinoma liver cancer pembrolizumab KEYTRUDA atezolizumab TECENTRIQ PD-1 PD-L1 immunecheckpoint immunotherapy ramucirumab cabozantinib KEYNOTE-224 SCRUM-Japan GI-SCREEN CELESTIAL REACH-2© krishnacreations / 123RF Stock Photo

    ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

    https://medi-paper.com/wp-content/uploads/2018/06/ASCO18-ASCO-2018-HCC-hepatocellular-carcinoma-liver-cancer-pembrolizumab-KEYTRUDA-atezolizumab-TECENTRIQ-PD-1-PD-L1-immunecheckpoint-immunotherapy-ramucirumab-cabozantinib-KEYNOTE-224-SCRUM-Japan-GI-SCREEN-CELESTIAL-REACH-2.jpg 1000 1500 Anne John Michael https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Anne John Michael2018-06-10 11:59:542018-08-23 10:33:26ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    FDA approves venetoclax in 2nd-line for patients with CLL or SLL

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-09 11:25:082018-09-25 17:51:30FDA approves venetoclax in 2nd-line for patients with CLL or SLL
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-06-06 16:07:462018-08-11 23:55:46FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy
    IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclcbravajulia / 123RF Stock Photo

    AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC

    https://medi-paper.com/wp-content/uploads/2018/05/IMPower150-Reck-Socinski-ELCC-AACR-2018-firstline-atezolizumab-bevacizumab-chemotherapy-non-squamous-nsclc.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-05-10 16:19:462018-05-24 09:31:31AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC
    US FDA approved CAR-t cell BiTE DAR-T cell CD19 Immunotherapies blinatumomab axicabtagene ciloleucel tisagenlecleucel

    US FDA approved CAR-T cell and BiTE immunotherapy – Updated 2-May-2018

    https://medi-paper.com/wp-content/uploads/2018/04/US-FDA-approved-CAR-t-cell-BiTE-DAR-T-cell-CD19-Immunotherapies-blinatumomab-axicabtagene-ciloleucel-tisagenlecleucel.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-05-02 10:00:352018-05-24 09:36:21US FDA approved CAR-T cell and BiTE immunotherapy – Updated 2-May-2018
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-30 13:35:562018-07-30 11:42:21Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma
    AACR 2018 First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer tumour-mutation burden CheckMate 227 NCT02477826Hywards / 123RF Stock Photo

    Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)

    https://medi-paper.com/wp-content/uploads/2018/04/First-line-Nivolumab-Ipilimumab-in-TMB-high-NSCLC-front-line-immunotherapy-for-non-small-cell-lung-cancer-CheckMate-227-NCT02477826.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-21 10:30:432018-05-24 09:37:03Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-19 13:36:062018-07-30 11:15:04FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)
    NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhikrishnacreations / 123RF Stock Photo

    Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC

    https://medi-paper.com/wp-content/uploads/2018/04/NCT02578680-Keynote189-pembrolizumab-chemotherapy-nsclc-NEJM-Leena-Gandhi.jpg 938 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-19 01:27:262018-05-24 09:37:16Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-16 13:59:012018-07-30 11:50:31Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC
    Keynote-042 Keynote-024 pembrolizumab nsclc keytruda nsclc non-squamous squamous PD-L1 expression 1% 20% 50% Tony Mok MD NCT02220894 Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

    Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

    https://medi-paper.com/wp-content/uploads/2018/04/Keynote-042-Keynote-024-pembrolizumab-nsclc-keytruda-nsclc-non-squamous-squamous-PD-L1-expression-1-20-50-Tony-Mok-MD-NCT02220894-Pembrolizumab-effective-in-frontline-NSCLC-with-low-PD-L1-expression.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-10 20:15:112018-05-24 09:37:32Pembrolizumab effective in frontline NSCLC with low PD-L1 expression
    Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

    Everolimus suspension approved in TSC-associated partial-onset seizures

    https://medi-paper.com/wp-content/uploads/2018/06/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925611846.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-04-10 14:07:302018-07-30 14:22:09Everolimus suspension approved in TSC-associated partial-onset seizures
    Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes

    I-O in Special Populations: Diabetes and Concomitant Steroids

    https://medi-paper.com/wp-content/uploads/2018/02/Herbert-Loong-on-irAEs-Immunotherapy-I-O-and-New-Onset-Diabetes-or-immune-mediated-diabetes.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-04-06 09:00:412018-08-11 23:56:01I-O in Special Populations: Diabetes and Concomitant Steroids

    Death due to cancer on the decline for most tumours in Europe

    https://medi-paper.com/wp-content/uploads/2018/03/1522336566_Oncology-Breast-CNS-Chemotherapy-Endocrine-GI-GU-Geriatric-Gynecologic-GYN-OB-Head-and-Neck-Haematology-Immunotherapy-Lung-Melanoma-Skin-NET-Paediatric-Pathology-Sarcoma-Surgery-Targeted-Therapy-Translational-03.jpg 277 450 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-03-31 11:03:502018-08-10 11:57:59Death due to cancer on the decline for most tumours in Europe
    immunotherapy I-O immunooncology nivolumab npc opdivo nasopharyngeal carcinoma brigette ma CUHK phase II nci-9742 study JCO journal of clinical oncology

    Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)

    https://medi-paper.com/wp-content/uploads/2018/03/nivolumab-npc-opdivo-nasopharyngeal-carcinoma-brigette-ma-CUHK-phase-II-nci-9742-study-JCO-journal-of-clinical-oncology.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-03-31 09:20:312018-05-24 09:38:41Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)
    ©aquir / 123RF Stock Photo

    FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%

    https://medi-paper.com/wp-content/uploads/2018/05/1526019694_US-FDA-Oncology-Haematology-Drug-Approvals-e1537929700820.jpg 1000 1495 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-03-29 14:21:342018-09-25 17:51:10FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%
    Making sense of immunotherapy in NSCLC

    Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

    https://medi-paper.com/wp-content/uploads/2018/03/Making-sense-of-immunotherapy-in-NSCLC.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-03-26 16:06:282018-07-31 23:06:54Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)
    manuela schmidinger sutent sunitinib ae management manuela schmidinger manuela schmidinger sutent sunitinib side-effect management sutent sunitinib toxicity management Sutent Sunitinib AE management toxicity management side-effect management sorafenib pazopanib axitinib regorafenib vandetanib cabozantinib lenvatinib bevacizumab VEGFR VEGF renal cell carcinoma RCC kidney cancer renal cell cancer schmidinger

    Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

    https://medi-paper.com/wp-content/uploads/2017/11/image.png 852 1471 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-11-29 22:12:232018-04-19 10:46:51Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects
    2016 pancreatic cancer awareness month IMM-101 plus Gemcitabine medipaper medical communications medical writer hire healthcare writers hong kong

    Do you know your lifetime risk on Pancreatic Cancer?

    https://medi-paper.com/wp-content/uploads/2016/11/2016-Pancreatic-Cancer-medipaper-medical-communications-medical-writer-hire-healthcare-writers-hong-kong.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-11-20 12:29:422018-02-09 14:08:00Do you know your lifetime risk on Pancreatic Cancer?
    HKBCF luminal breast cancer can cdk46 inhibition by palbociclib improve on chemotherapy medipaper medical writer hong kong

    Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?

    https://medi-paper.com/wp-content/uploads/2017/10/HKBCF-luminal-breast-cancer-can-cdk46-inhibition-by-palbociclib-improve-on-chemotherapy-medipaper-medical-writer-hong-kong.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-10-25 22:58:382018-02-09 14:08:00Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?
    us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg

    Pembrolizumab approved for advanced gastric cancer

    https://medi-paper.com/wp-content/uploads/2018/07/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925322207.jpg 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-22 23:33:522018-07-26 15:04:47Pembrolizumab approved for advanced gastric cancer
    us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg

    Nivolumab approved for sorafenib-refractory HCC

    https://medi-paper.com/wp-content/uploads/2018/07/us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious-e1537925322207.jpg 1000 1495 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-22 23:21:412018-07-26 11:42:35Nivolumab approved for sorafenib-refractory HCC
    Nivolumab Renal Cell Cancer Symposium Highlight

    Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy

    https://medi-paper.com/wp-content/uploads/2017/09/Nivolumab-Renal-Cell-Cancer-Symposium-Highlight.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-09-19 23:04:512018-08-11 23:56:17Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy
    adjuvant hormonal therapy

    Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?

    https://medi-paper.com/wp-content/uploads/2017/08/adjuvant-hormonal-therapy.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-07-05 22:46:312018-02-09 14:08:00Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?
    2017 CICS immunooncology annual meeting oncology medical writer medipaper medical communications

    Interested in Attending an Immunooncology Conference?

    https://medi-paper.com/wp-content/uploads/2017/02/2017-CICS-immunooncology-annual-meeting-oncology-medical-writer-medipaper-medical-communications.png 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2017-06-21 16:05:482018-02-09 14:08:00Interested in Attending an Immunooncology Conference?
    esmo 2016 breast cancer ribociclib palbociclib abemaciclib data medipaper medicall writer

    ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data

    https://medi-paper.com/wp-content/uploads/2016/10/ESMO-2016-Breast-Cancer-Palbociclib-Ribociclib-Abemaciclib-data-MediPaper-Medical-Writer-e1478671413852.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-11-09 16:00:442018-05-11 17:14:06ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data
    PD-L1 Biomarker for Response DAKO 22C3 - MediPaper Medical Communications

    PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data

    https://medi-paper.com/wp-content/uploads/2016/08/PD-L1-Biomarker-for-Response-DAKO-22C3-MediPaper-Medical-Communications.png 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-26 14:00:352018-05-11 17:21:18PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data
    Biomarkers Ipilimumab Treatment MediPaper Medical Communications

    Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies

    https://medi-paper.com/wp-content/uploads/2016/10/Biomarkers-Ipilimumab-Treatment-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-24 10:12:072018-05-11 17:18:58Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies
    ESMO 2016 ipilimumab data medipaper medical communications

    ESMO16 Ipilimumab data – Download the PPT

    https://medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-ipilimumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-11 11:10:102018-05-11 17:28:19ESMO16 Ipilimumab data – Download the PPT
    ESMO 2016 pembrolizumab data medipaper medical communications

    ESMO16 Pembrolizumab data – Download the PPT

    https://medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-pembrolizumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-10 21:08:122018-05-11 17:28:28ESMO16 Pembrolizumab data – Download the PPT
    ESMO 2016 durvalumab avelumab tremelimumab data medipaper medical communications

    ESMO16 Durvalumab, Avelumab, Tremelimumab Data – Download the PPT

    https://medi-paper.com/wp-content/uploads/2016/10/ESMO-2016-durvalumab-avelumab-tremelimumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-10 10:30:512018-05-11 17:28:38ESMO16 Durvalumab, Avelumab, Tremelimumab Data – Download the PPT
    ESMO 2016 atezolizumab data medipaper medical communications

    ESMO16 Atezolizumab data – Download the PPT

    https://medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-atezolizumab-data-medipaper.jpg 665 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-09 17:50:232018-05-11 17:28:52ESMO16 Atezolizumab data – Download the PPT
    ESMO 2016 nivolumab data medipaper medical communications

    ESMO16 Nivolumab data – Download the PPT

    https://medi-paper.com/wp-content/uploads/2016/09/ESMO-2016-nivolumab-data-medipaper.jpg 667 1000 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-10-09 16:30:582018-05-11 17:29:00ESMO16 Nivolumab data – Download the PPT
    cancer awareness improves outcome medipaper medical communications

    Cancer symptom awareness linked to survival

    https://medi-paper.com/wp-content/uploads/2016/09/cancer-awareness-improves-outcome-medipaper-medical-communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-30 21:33:432018-02-09 13:51:10Cancer symptom awareness linked to survival
    2016 ASCO ovarian cancer guidelines neo-adjuvant chemotherapy medipaper medical communications

    ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated

    https://medi-paper.com/wp-content/uploads/2016/09/2016-asco-ovarian-cancer-guidelines-neo-adjuvant-chemotherapy-medipaper-medical-communications-e1478394814429.png 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-27 21:53:422018-02-09 14:07:58ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated
    IMM-101 plus gemcitabine-medipaper medical communications BW

    IMM101 plus Gemcitabine Hopeful in Metastatic Pancreatic Cancer

    https://medi-paper.com/wp-content/uploads/2016/09/IMM-101-plus-gemcitabine-medipaper-medical-communications_medical_writer_hong_kong.jpg 844 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-25 00:19:582018-02-09 13:51:09IMM101 plus Gemcitabine Hopeful in Metastatic Pancreatic Cancer
    palbociclib-first-in-class

    Palbociclib (Ibrance®): First in Class CDK4/6 Inhibitor

    https://medi-paper.com/wp-content/uploads/2016/04/palbociclib-first-in-class.jpg 662 1095 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-17 00:46:162018-05-11 17:13:52Palbociclib (Ibrance®): First in Class CDK4/6 Inhibitor
    Ki67 breast cancer medical writer epotomics

    Ki67 in Breast Cancer: an overview

    https://medi-paper.com/wp-content/uploads/2016/04/Ki67-breast-cancer-medical-writer-epotomics-com.png 998 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-09-06 00:07:072018-05-11 17:15:08Ki67 in Breast Cancer: an overview
    ASCO 2016 ribociclib & abemaciclib Data - MediPaper Medical Communications

    ASCO16 Ribociclib & Abemaciclib Data

    https://medi-paper.com/wp-content/uploads/2016/06/ribociclib-abemaciclib-ASCO2016-Data-MediPaper-Medical-Communications.jpg 1033 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-05 23:30:482018-05-11 17:17:01ASCO16 Ribociclib & Abemaciclib Data
    ASCO 2016 Palbociclib Data MediPaper Medical Communications

    ASCO16 palbociclib (Ibrance©) Data

    https://medi-paper.com/wp-content/uploads/2016/06/ASCO-2016-Palbociclib-Data-MediPaper-Medical-Communications.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-04 22:51:302018-05-11 17:16:17ASCO16 palbociclib (Ibrance©) Data
    ASCO 2016 Avelumab Durvalumab and Tremelimumab Data - MediPaper Medical Communications

    ASCO16 Avelumab, Durvalumab, and Tremelimumab

    https://medi-paper.com/wp-content/uploads/2016/06/ASCO-2016-Azelumab-Durvalumab-and-Tremelimumab-Data.jpg 938 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-03 11:57:432018-05-11 17:25:17ASCO16 Avelumab, Durvalumab, and Tremelimumab
    asco 2016 atezolizumab data

    ASCO16 Atezolizumab (Tecentriq©) Data

    https://medi-paper.com/wp-content/uploads/2016/06/asco-2016-atezolizumab-data.jpg 1200 1800 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-06-02 15:15:132018-05-11 17:25:04ASCO16 Atezolizumab (Tecentriq©) Data
    ASCO2016 ipilimumab data - MediPaper Medical Communications

    ASCO16 Ipilimumab (Yervoy©) Data

    https://medi-paper.com/wp-content/uploads/2016/05/ASCO2016-ipilimumab-data-MediPaper-Medical-Communications.jpg 938 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-31 13:05:442018-05-11 17:22:00ASCO16 Ipilimumab (Yervoy©) Data
    asco 2016 nivolumab medipaper medical communications

    ASCO16 Nivolumab (Opdivo©) Data

    https://medi-paper.com/wp-content/uploads/2016/05/asco-2016-nivolumab.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-29 00:44:422018-05-11 17:25:59ASCO16 Nivolumab (Opdivo©) Data
    asco 2016 pembrolizumab medipaper medical communications

    ASCO16 Pembrolizumab (Keytruda©) Data

    https://medi-paper.com/wp-content/uploads/2016/05/asco-2016-pembrolizumab.jpg 851 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-29 00:23:322018-05-11 17:22:45ASCO16 Pembrolizumab (Keytruda©) Data
    PreviousNext
    1 reply

    Trackbacks & Pingbacks

    1. Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC says:
      5th October 2018 at 5:32 PM

      […] inhibitor-naïve patients with ALK-rearranged non-small cell lung cancer (NSCLC) when compared to crizotinib, as concluded from the ALTA-1L […]

      Log in to Reply

    Leave a Reply

    Want to join the discussion?
    Feel free to contribute!

    Leave a Reply Cancel reply

    You must be logged in to post a comment.

    © Copyright 2018 MediPaper Medical Communications Ltd. – Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations – XalkoriⓇ/crizotinib in Asian non-small cell lung cancer patients with ROS-1 alterations

    Therapeutic Areas

    Or, sign up for our newsletter


    © 2016-2021 MediPaper Medical Communications Ltd. | Website by [’mediPr] | 醫學作家香港 | Privacy Policy | Cookie Policy
    • Facebook
    • LinkedIn
    • Twitter
    • Instagram
    • Pinterest
    • Youtube
    • Mail
    • Rss
    Interest Builds in CSF1R for Targeting Tumor Microenvironment Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes I-O in Special Populations: Diabetes and Concomitant Steroids
    Scroll to top

    This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

    OKPrivacy Settings

    Cookies and Privacy on medi-paper.com



    Cookie Policy

    How MediPaper uses cookies is explained in our Cookie Policy

    Privacy Policy

    Read MediPaper's Privacy Policy

    Google Analytics cookies

    These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

    If you do not want that we track your visist to our site you can disable tracking in your browser here:

    Other external services

    We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

    Google Webfont Settings:

    Google Map Settings:

    Vimeo and Youtube video embeds:

    Accept settingsHide notification only
    MediPaper Medical Communications Agency Hong Kong Blog